SCHEMBL5016202

SCHEMBL5016202

c1ccc(CCCNc2cc(-n3cccn3)nc(-c3cccs3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.43
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
GBA1 P04062 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PDE5A O76074 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
ABCG2 Q9UNQ0 2/20 0.40
CXCR4 P61073 1/20 0.38
HPGD P15428 2/20 0.37
BRD4 O60885 1/20 0.37
GAA P10253 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ADORA2A P29274 4/20 0.37
ADORA1 P30542 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017845 0.88 GBA1 (0.42) ALDH1A1GBA1MEN1KMT2ACXCR4
SCHEMBL5026217 0.85 GSK3B (0.40) KDM4EALDH1A1MAPTGBA1MEN1
SCHEMBL5016142 0.85 ADORA2A (0.39) KDM4EALDH1A1MAPTGBA1MEN1
SCHEMBL5016164 0.84 KDM4E (0.45) KDM4EALDH1A1MAPTGBA1HTT
SCHEMBL6038241 0.83 BRD4 (0.48) GBA1CXCR4BRD4ADORA2AADORA1
SCHEMBL5016108 0.82 ADORA2A (0.48) KDM4EALDH1A1MAPTGBA1MEN1
SCHEMBL3633401 0.82 KDM4E (0.46) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL5026342 0.81 ADORA2A (0.52) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL5016102 0.80 SMN1; SMN2 (0.49) KDM4EALDH1A1MAPTKMT2ALMNA
SCHEMBL5016182 0.80 ADORA2A (0.59) KDM4EALDH1A1MAPTPDE5AABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US claimed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 NR1H4 948/4885KDM4E 3504/4885ALDH1A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.